|
Advanced Melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
PLX4032 is commonly used in the treatment of advanced melanoma patients with BRAF-V600E mutation.
|
31810919 |
2019 |
|
Sarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis.
|
30662270 |
2019 |
|
Malignant neoplasm of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis.
|
30662270 |
2019 |
|
Cerebellar Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The cerebellar tumor revealed neither a BRAF V600E nor a H3F3A mutation but a homozygous CDKN2A/B deletion.
|
30203362 |
2018 |
|
Pleural Effusion, Malignant
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib.
|
27923714 |
2017 |
|
Carcinomatosis of peritoneal cavity
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, the incidence of the BRAF V600E mutation was significantly higher in PC than in non-PC patients (27.7% versus 7.3%, p<0.01).
|
26925640 |
2016 |
|
Neuroendocrine Tumors
|
|
0.010 |
GeneticVariation
|
BEFREE |
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
|
26684240 |
2016 |
|
Epithelioid glioblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was present in four eGBMs and four ePXAs.
|
26238627 |
2016 |
|
Monosomy
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this series, histone H3-K27M mutation was mutually exclusive with IDH1 mutation and EGFR amplification, rarely co-occurred with BRAF-V600E mutation, and was commonly associated with p53 overexpression, ATRX loss (except in pontine gliomas), and monosomy 10.
|
26517431 |
2016 |
|
Gastro-enteropancreatic neuroendocrine tumor
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.
|
26684240 |
2016 |
|
Gastrointestinal Stromal Tumors
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aims of this study were to investigate whether succinate dehydrogenase B (SDHB), insulin growth factor 1 receptor (IGF1R), HER2, epidermal growth factor receptor (EGFR) and/or BRAF V600E immunohistochemistry could screen for wild-type gastrointestinal stromal tumours (GISTs), and to determine what proportion of wild-type GISTs expressed these proteins and might therefore represent candidates for targeted therapies.
|
25659413 |
2015 |
|
BRONCHIAL ADENOCARCINOMA
|
|
0.010 |
GeneticVariation
|
BEFREE |
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
|
25466451 |
2015 |
|
Glioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.
|
26023796 |
2015 |
|
Secondary Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The utility of immunohistochemistry (IHC) as an alternative approach for detection of BRAF(V600E) in the thoracic metastases of sporadic mCRC patients has not been evaluated until now.
|
24798160 |
2014 |
|
Brain Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
PKM2-regulated MLC2 phosphorylation, which is greatly enhanced by EGF stimulation or EGFRvIII, K-Ras G12V and B-Raf V600E mutant expression, plays a pivotal role in cytokinesis, cell proliferation and brain tumour development.
|
25412762 |
2014 |
|
Adenocarcinoma of large intestine
|
|
0.010 |
GeneticVariation
|
BEFREE |
Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
|
23763264 |
2013 |
|
Malignant neoplasm of colon stage IV
|
|
0.010 |
GeneticVariation
|
BEFREE |
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
|
23792568 |
2013 |
|
Colorectal Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
To verify the technical characteristics of the microarray system for the correct identification of the KRAS mutational status at the two hotspot codons 12 and 13 and of the BRAF(V600E) mutation in colorectal tumor, we selected 75 samples previously characterized by conventional and CO-amplification at Lower Denaturation temperature-PCR (COLD-PCR) followed by High Resolution Melting analysis and direct sequencing.
|
23536897 |
2013 |
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Marinesco-Sjogren syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |
|
Pleomorphic Xanthoastrocytoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We find that PXAs are genetically defined by the combination of CDKN2A biallelic inactivation and RAF alterations that were present in all 19 cases, most commonly as CDKN2A homozygous deletion and BRAF p.V600E mutation but also occasionally BRAF or RAF1 fusions or other rearrangements.
|
30051528 |
2019 |
|
Childhood Pleomorphic Xanthoastrocytoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We find that PXAs are genetically defined by the combination of CDKN2A biallelic inactivation and RAF alterations that were present in all 19 cases, most commonly as CDKN2A homozygous deletion and BRAF p.V600E mutation but also occasionally BRAF or RAF1 fusions or other rearrangements.
|
30051528 |
2019 |
|
Malignant neoplasm of thyroid
|
|
0.020 |
GeneticVariation
|
BEFREE |
The BM probe not only enabled sensitive detection of two types of EGFR-associated point mutations located in GC-rich regions, but also successfully identified the BRAF V600E mutation in the serum from a thyroid cancer patient which could not be detected by the conventional sequencing method.
|
28201758 |
2017 |